Search Result

Results for "

non-enzymatic protein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (3) DNA/RNA Synthesis (1) GABA Receptor (1) Histone Methyltransferase (1) NO Synthase (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Inflammation/Immunology (1) Metabolic Disease (6) Neurological Disease (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Targets Recommended: TNK1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-NP165

Advanced glycation end products	Biochemical Assay Reagents	Metabolic Disease
Advanced glycation end products is a series of stable compounds produced by non-enzymatic reactions of reducing sugars with proteins, lipids or nucleic acids. Advanced glycation end products is often used as a target for evaluating the inhibitory effects of anti-glycosylation compounds .

HY-W286743

Nε-(Carboxymethyl)-L-lysine CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine	Biochemical Assay Reagents	Cardiovascular Disease Metabolic Disease Cancer
Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

HY-139427

3-Methylglutaconic acid β-Methylglutaconic acid	GABA Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research .

HY-145685

RECQL5-IN-1	DNA/RNA Synthesis	Cancer
RECQL5-IN-1 (Compound 4a) acts as an orally effective RECQL5 inhibitor (targeting both enzymatic and nonenzymatic domain). RECQL5-IN-1 is a potent inhibitor of RECQL5 helicase activity (IC₅₀=46.3 nM), stabilizes the interaction between RECQL5-RAD51 proteins, causes RAD51 aggregation and homologous recombination repair (HRR) inhibition, thereby exhibiting selective cytotoxicity in RECQL5-expressing cancer cells .

HY-141508

Flazin	Xanthine Oxidase NO Synthase	Neurological Disease Metabolic Disease Inflammation/Immunology
Flazin is a non-enzymatic protein glycation inhibitor, also inhibits peroxynitrite (ONOO ^-), with an IC₅₀ value of 85.31 μM for bovine serum albumin (BSA) glycation and an EC₅₀ value of 71.99 μM for ONOO ^-. Flazin can be used for researching diabetes and neuronal disorders. Flazin also can used as a lipid droplet (LD) regulator against lipid disorders, and a xanthine oxidase (XOD) inhibitor .

HY-113033

Pentosidine	Others	Neurological Disease Metabolic Disease
Pentosidine is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .

HY-113033A

Pentosidine TFA	Biochemical Assay Reagents	Neurological Disease Metabolic Disease
Pentosidine TFA is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine TFA is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .

HY-172769

CM112	Histone Methyltransferase	Cancer
CM112 is a selective protein arginine methyltransferase 1 (PRMT1) degrader by tethering hydrophobic tag, adamantane, to MS023 with a 5-PEG linker. CM112 induces the degradation of PRMT1 in various solid cancer cell lines. CM112 can also target the nonenzymatic function of PRMT1 by downregulating the stability of the orphan receptor TR3. CM112 is promising for research of cancers .

Cat. No.	Product Name	Type

HY-NP165

Advanced glycation end products	Native Proteins
Advanced glycation end products is a series of stable compounds produced by non-enzymatic reactions of reducing sugars with proteins, lipids or nucleic acids. Advanced glycation end products is often used as a target for evaluating the inhibitory effects of anti-glycosylation compounds .

HY-W286743

Nε-(Carboxymethyl)-L-lysine CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine	Biochemical Assay Reagents
Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

Nε-(Carboxymethyl)-L-lysine

CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine

Biochemical Assay Reagents

Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-141508

Flazin	Simaroubaceae Source classification Plants Indole Alkaloids Brucea javanica (L.) Merr.	Xanthine Oxidase NO Synthase
Flazin is a non-enzymatic protein glycation inhibitor, also inhibits peroxynitrite (ONOO ^-), with an IC₅₀ value of 85.31 μM for bovine serum albumin (BSA) glycation and an EC₅₀ value of 71.99 μM for ONOO ^-. Flazin can be used for researching diabetes and neuronal disorders. Flazin also can used as a lipid droplet (LD) regulator against lipid disorders, and a xanthine oxidase (XOD) inhibitor .

HY-113033

Pentosidine	Structural Classification Natural Products Source classification Disease markers Endogenous metabolite	Others
Pentosidine is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

non-enzymatic protein

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Natural
Products